secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0001493152-24-029379
Event type: other_material
Sentiment:  positive
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics to present POZ-lipid data at mRNA Summit; no anti-PEG antibody response
--------------------------------------------------------------------------------

- Randall Moreadith, MD, PhD, CDO, will present at 4th Annual mRNA-Based Therapeutics Summit in Boston, July 29-31, 2024.
- POZ-lipid does not induce IgM or IgG antibody response in repeated in vivo dosing, unlike current PEG-lipids in mRNA vaccines.
- This technology may reduce risk of serious adverse events like anaphylaxis linked to anti-PEG antibodies.
- Presentation scheduled for 9:00 AM ET on Monday, July 29, 2024.
- Serina's POZ Platform is being developed for neurological diseases, cancer, and other indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224029379/0001493152-24-029379-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224029379/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-029379

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer